WO2006119211A3 - Methods and compositions for treating ocular disorders - Google Patents

Methods and compositions for treating ocular disorders Download PDF

Info

Publication number
WO2006119211A3
WO2006119211A3 PCT/US2006/016667 US2006016667W WO2006119211A3 WO 2006119211 A3 WO2006119211 A3 WO 2006119211A3 US 2006016667 W US2006016667 W US 2006016667W WO 2006119211 A3 WO2006119211 A3 WO 2006119211A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
ocular disorders
methods
treating ocular
compounds
Prior art date
Application number
PCT/US2006/016667
Other languages
French (fr)
Other versions
WO2006119211A2 (en
Inventor
Michael Mclane
Roger Vogel
Avinash Desai
Kenneth Holroyd
Roy C Levitt
Original Assignee
Genaera Corp
Michael Mclane
Roger Vogel
Avinash Desai
Kenneth Holroyd
Roy C Levitt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genaera Corp, Michael Mclane, Roger Vogel, Avinash Desai, Kenneth Holroyd, Roy C Levitt filed Critical Genaera Corp
Publication of WO2006119211A2 publication Critical patent/WO2006119211A2/en
Publication of WO2006119211A3 publication Critical patent/WO2006119211A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

Aminosterol compounds are described that are useful in combination with photodynamic therapy with verteporfin, rostaporfin or other photo-activated compounds for treating ocular disorders. Compositions comprising such aminosterols and photo-activated compounds and methods of using such aminosterols compounds in combination with photodynamic therapy with photo-activated compounds are also employed for treating ocular disorders.
PCT/US2006/016667 2005-05-02 2006-05-02 Methods and compositions for treating ocular disorders WO2006119211A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67628405P 2005-05-02 2005-05-02
US60/676,284 2005-05-02

Publications (2)

Publication Number Publication Date
WO2006119211A2 WO2006119211A2 (en) 2006-11-09
WO2006119211A3 true WO2006119211A3 (en) 2007-08-30

Family

ID=37028634

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/016667 WO2006119211A2 (en) 2005-05-02 2006-05-02 Methods and compositions for treating ocular disorders

Country Status (1)

Country Link
WO (1) WO2006119211A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012024298A1 (en) * 2010-08-17 2012-02-23 Ohr Pharmaceutical, Inc. Ophthalmic formulations of squalamine
WO2020028791A1 (en) * 2018-08-03 2020-02-06 Enterin Laboratories Low dosage intranasal aminosterol dosage forms and methods of using the same
US11464789B2 (en) 2018-08-03 2022-10-11 Enterin, Inc. Aminosterol compositions and methods of using the same for treating schizophrenia
EP3829587A4 (en) * 2018-08-03 2022-07-20 Enterin, Inc. Compositions and methods for treating brain-gut disorders

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996015131A1 (en) * 1994-11-10 1996-05-23 Pfizer Pharmaceuticals Inc. Macrocyclic lactone compounds and their production process
US6147060A (en) * 1996-04-26 2000-11-14 Magainin Pharmaceuticals Treatment of carcinomas using squalamine in combination with other anti-cancer agents
US20010046521A1 (en) * 1996-04-26 2001-11-29 Michael Zasloff Treatment of carcinomas using squalamine in combination with other anti-cancer agents or modalities
US20020127224A1 (en) * 2001-03-02 2002-09-12 James Chen Use of photoluminescent nanoparticles for photodynamic therapy
US20030082183A1 (en) * 2000-11-01 2003-05-01 Wheeler Larry A. Methods and compositions for treatment of ocular neovascularization and neural injury
US20030083649A1 (en) * 2001-02-15 2003-05-01 Margaron Philippe Maria Clotaire Method for reducing or preventing PDT related inflammation
WO2004027027A2 (en) * 2002-09-18 2004-04-01 Trustees Of The University Of Pennsylvania Method of inhibiting choroidal neovascularization
EP1420027A2 (en) * 1995-06-07 2004-05-19 Genaera Corporation Aminosterol compounds useful as inhibitors of the sodium/proton exchanger (NHE), pharmaceutical methods and compositions employing such inhibitors, and processes for evaluating the NHE-inhibitory efficacy of compounds

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996015131A1 (en) * 1994-11-10 1996-05-23 Pfizer Pharmaceuticals Inc. Macrocyclic lactone compounds and their production process
EP1420027A2 (en) * 1995-06-07 2004-05-19 Genaera Corporation Aminosterol compounds useful as inhibitors of the sodium/proton exchanger (NHE), pharmaceutical methods and compositions employing such inhibitors, and processes for evaluating the NHE-inhibitory efficacy of compounds
US6147060A (en) * 1996-04-26 2000-11-14 Magainin Pharmaceuticals Treatment of carcinomas using squalamine in combination with other anti-cancer agents
US20010046521A1 (en) * 1996-04-26 2001-11-29 Michael Zasloff Treatment of carcinomas using squalamine in combination with other anti-cancer agents or modalities
US20030082183A1 (en) * 2000-11-01 2003-05-01 Wheeler Larry A. Methods and compositions for treatment of ocular neovascularization and neural injury
US20030083649A1 (en) * 2001-02-15 2003-05-01 Margaron Philippe Maria Clotaire Method for reducing or preventing PDT related inflammation
US20020127224A1 (en) * 2001-03-02 2002-09-12 James Chen Use of photoluminescent nanoparticles for photodynamic therapy
WO2004027027A2 (en) * 2002-09-18 2004-04-01 Trustees Of The University Of Pennsylvania Method of inhibiting choroidal neovascularization

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CIULLA T A ET AL: "A phase II, multi-center, randomized, controlled, masked study of the effects of squalamine lactate in combination with Visudyne in patients with subfoveal choroidal neovascularization associated with age-related macular degeneration", INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, ASSOCIATION FOR RESEARCH IN VISION AND, US, vol. 46, no. Suppl S, 2005, pages 2363, XP008080305, ISSN: 0146-0404 *

Also Published As

Publication number Publication date
WO2006119211A2 (en) 2006-11-09

Similar Documents

Publication Publication Date Title
NL301145I2 (en) Tirbanibulin
WO2006133271A3 (en) Compositions and methods relating to target-specific photodynamic therapy
WO2005094376A3 (en) Synergistic methods and compositions for treating cancer
EP1954274B8 (en) Substituted quinolones and methods of use
WO2007053573A3 (en) Treatment of cancer with sorafenib
GB2442915B (en) Perylenequinone derivatives and uses thereof
WO2003082208A3 (en) Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders
WO2005048948A3 (en) Urea derivatives as kinase modulators
WO2004035590A3 (en) Meso-substituted porphyrins
WO2006091459A3 (en) Compositions and methods for treating vascular permeability
EP1791544A4 (en) Quinazoline derivatives as metabolically inert antifolate compounds
WO2008076278A3 (en) Methods of cancer treatment with igf1r inhibitors
TW200716141A (en) Compositions and methods for treatment for neoplasms
WO2007145704A3 (en) Gemcitabine combination therapy
WO2006113483A3 (en) Methods and compositions for treating or preventing cancer
WO2006109301A3 (en) Molecules and methods of using same for treating mcp-1/ccr2 associated diseases
NO20082425L (en) Formulations comprising jorumycin, reni-eramycin, safracin or saframycin-related compounds for the treatment of proliferative diseases
WO2006050373A3 (en) Methods and compositions for modulating apoptosis
WO2006096492A3 (en) Compositions and methods for reducing photosensitivity associated with photodynamic therapy
WO2006102375A3 (en) Methods for avoiding edema in the treatment or prevention of pparϝ-responsive diseases, including cancer
WO2006119211A3 (en) Methods and compositions for treating ocular disorders
WO2005000208A3 (en) Combination therapy for the treatment of neoplasms
WO2007048097A3 (en) Anbrosteeone derivatives and method of use thereof
HK1102626A1 (en) Compositions and methods for the treatment and prevention of hyperproliferative diseases
AU2006278227A8 (en) Methods for the treatment and prevention of abnormal cell proliferation using TACI-fusion molecules

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 06752028

Country of ref document: EP

Kind code of ref document: A2